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The dysbiosis signature of Fusobacterium 
nucleatum in colorectal cancer-cause 
or consequences? A systematic review
Maryam Ranjbar1, Rasoul Salehi2,3, Shaghayegh Haghjooy Javanmard1, Laleh Rafiee1, Habibollah Faraji4, 
Sima jafarpor3, Gordon A. Ferns5, Majid Ghayour‑Mobarhan6, Mostafa Manian7 and Reza Nedaeinia3*  
Abstract 
Colorectal cancer (CRC) is the third most common cause of cancer globally and the fourth attributable cause of 
mortality and morbidity due to cancer. An emerging factor contributing to CRC is the gut microbiota and the cel‑
lular changes associated with it. Further insights on this may help in the prevention, diagnosis and new therapeutic 
approaches to colorectal cancer. In most cases of CRC, genetic factors appear to contribute less to its aetiology than 
environmental and epigenetic factors; therefore, it may be important to investigate these environmental factors, their 
effects, and the mechanisms that may contribute to this cancer. The gut microbiota has recently been highlighted 
as a potential risk factor that may affect the structural components of the tumor microenvironment, as well as free 
radical and enzymatic metabolites directly, or indirectly. Many studies have reported changes in the gut microbiota of 
patients with colorectal cancer. What is controversial is whether the cancer is the cause or consequence of the change 
in the microbiota. There is strong evidence supporting both possibilities. The presence of Fusobacterium nucleatum in 
human colorectal specimens has been demonstrated by RNA‑sequencing. F. nucleatum has been shown to express 
high levels of virulence factors such as FadA, Fap2 and MORN2 proteins. Our review of the published data suggest that 
F. nucleatum may be a prognostic biomarker of CRC risk, and hence raises the potential of antibiotic treatment of F. 
nucleatum for the prevention of CRC.
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Introduction
CRC is one of the most common malignancies of men 
and women in most countries [1, 2]. The third most com-
mon cause of cancer and the fourth leading cause of can-
cer-related deaths [3]. More than 1.2 million new cases 
of CRC are reported annually throughout the world [4]. 
Identification of the microbial mechanisms involved in 
the etiology of CRC and the recognition of the associated 
cellular changes as one of the factors in the development 
of cancer may contribute to cancer prevention, its early 
diagnosis and potentially new therapies for CRC. The 
trend is for a projected increase in CRC by 60% to more 
than 2.2 million new cases, and 1.1 million cancer deaths 
by the year 2030 [3]. This increase in prevalence has 
caused considerable debate about the most appropri-
ate prevention approaches. These predictions represent 
a major problem in developing and developed countries 
in the public health sector [5]. There has been a global 
increase in the standardised rate of the age of CRC from 
1990 to 2017 with considerable heterogeneity at regional 
and national level. There has been a decline in the age-
standardized death and disability-adjusted life-years 
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criteria, CRC is the world’s 36th leading cause of death 
from disease in 2017 and the fourth most common cause 
of cancer. The gut microbiota may be one environmental 
risk factor predisposing to CRC [7]. Bacteria are found 
throughout the human body, but especially in the diges-
tive tract [8]. The gut at birth is sterile, but some organ-
isms enter it soon after birth. In breastfeed infants, the 
gut contains a large number of Lactic acid bacteria and 
Lactobacilli, streptococci, for example bifidobacterium. 
The gut microflora changes with changes in dietary hab-
its and the selection of adult dietary patterns [9]. Gut 
bacteria are important for the synthesis of vitamin K, 
and for the conversion of bile pigments and bile acids to 
secondary bile acids [10]. In addition, these bacteria are 
involved in the uptake of food and metabolic products 
and have antagonistic effects with microbial pathogens. 
The microbial flora of the gut produces ammonium and 
other metabolic products absorbed from the intestinal 
mucosa and can participate in the occurrence of hepatic 
coma. Anaerobic colonic bacteria, such as Bacteroides 
fragilis, Clostridium and Peptostreptococcus play a role 
in the progress of intra-abdominal abscesses [11]. There-
fore, intestinal microbes appear to play a crucial role in 
digestive function and health [12, 13]. It has been pro-
posed that commensal bacteria in the colon play a vital 
role in the development of CRC [14]. Various studies 
have shown that chronic infections can be important fac-
tors in the development of cancer. Gastric, liver, and cer-
vical cancers are caused by Helicobacter, Hepatitis B and 
C and human Papillomavirus, respectively [15, 16]. These 
pathogens activate tumor signaling pathways like NF-kB, 
STAT3 [15–17]. There is good evidence for a relationship 
between gut microbiota and CRC [18]. This is proposed 
to be due to the expression of proteins that have antia-
poptotic, growth factor or cytokine that enhance can-
cer cell growth, metastasis or resistance to therapy [17]. 
However, F. nucleatum has been shown to also express 
high levels of virulence factors such as FadA, Fap2 and 
MORN2 proteins [19]. Studies have demonstrated that 
the dominant microbiome is very similar in primary and 
metastatic tumors [20]. It is assumed that Fusobacterium 
moves to distant sites with primary tumor cells as a part 
of metastatic tissue colonization. This indicates that the 
tumor microbiomes are the essential components of the 
cancerous microenvironment [20, 21].
Objectives
In this paper, we aimed to examine the potential role of 
the gut microbiome, especially F. nucleatum, in inhibiting 
the immune system in CRC and the stimulatory effects 
of its surface proteins on the establishment or dissemi-
nation of CRC and stimulation of its tumorigenic signals. 
Also, the role of F. nucleatum and its virulence factors 
in the development of CRC in particular are systematic 
reviewed. The cellular signals associated with the creation 
of tumors activated by bacteria will also be explained.
Search strategy
The protocol was performed in accordance with the pre-
ferred reporting items for Systematic reviews and Meta-
Analyses (PRISMA) guidelines [22], outlined in Table 1. 
The following databases were searched: MEDLINE, 
Embase via PubMed, Scopus, Web of Science database 
and Google Scholar. A manual search was used to find 
reference lists of related articles and reviews. In order to 
locate reference lists of relevant publications and reviews, 
a manual search was used. The above manual search was 
made in order to find articles that were not identified by 
internet searches. The authors were consulted to collect 
further information in  situations where it was needed. 
Language constraints have been imposed for the search 
or collection of English publications written in Decem-
ber 2020. The following key- words were used in this 
search: [(Colorectal[Title/Abstract] OR Intestinal[Title/
Abstract]) AND (Neoplasm*[Title/Abstract] OR 
Carcinoma*[Title/Abstract] OR Cancer*[Title/Abstract] 
OR Tumor*[Title/Abstract] OR Malignanc*[Title/
Abstract])] OR [Adenoma*[Title/Abstract] AND (Colon 
[Title/Abstract] OR Intestin* [Title/Abstract] OR 
colonic [Title/Abstract] OR Polypos* [Title/Abstract])] 
AND [(fecal[Title/Abstract] OR faecal[Title/Abstract] 
OR feces[Title/Abstract]) AND (Fusobacteri*[Title/
Abstract] OR F. nucleatum[Title/Abstract])] AND 
[Microbio*[Title/Abstract] OR Microbial[Title/Abstract] 
OR Diet[Title/Abstract] OR Dysbios*[Title/Abstract] 
OR Dysbacterios*[Title/Abstract] OR MicroRNA[Title/
Abstract] OR miRNAs[Title/Abstract] OR “Micro 
RNA” [Title/Abstract] OR miRNA[Title/Abstract]] 
OR [Marker*[Title/Abstract] AND (Tumor[Title/
Abstract] OR Carcinogen*[Title/Abstract] OR 
Neoplasm*[Title/Abstract] OR Cancer[Title/Abstract])) 
OR (Biomarker*[Title/Abstract] AND (Tumor[Title/
Abstract] OR Carcinogen*[Title/Abstract] OR 
Neoplasm*[Title/Abstract] OR Cancer[Title/Abstract])) 
OR immunomodulator*[Title/Abstract]].
Study selection
Three hundred and ninety one unique records were 
checked by title and abstract to assess their eligibility 
for inclusion in the project after finding a total of 497 
papers and deleting the duplicate records. The full texts 
of 202 publications were then checked and the related 
articles were chosen according to the study inclusion cri-
teria (Fig.  1). The inclusion criteria were: Studies meas-
uring the association of Fusobacterium nucleatum with 
colorectal cancer in patients and the published studies 
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in English language. The exclusion criteria were: 1—No 
access to full-text articles 2—Case reports, randomized 
clinical trials and review articles 3—Studies on teenagers 
and 4—Duplicate records were excluded. Figure 1 shows 
the selection process for articles. Data collected using 
EndNote software. The main characteristics are summa-
rized in Table 1.
Colorectal cancer
Cancer usually arises due to the failure of mechanisms 
controlling cell growth and proliferation. This control 
system responds to growth inhibition, growth and death 
signals. Colorectal carcinogenesis involves a series of 
well-defined changes that begin with a benign mucosal 
lesion called a polyp and can progress to malignancy 
leading to cancerous changes such as hyperplasia, ade-
noma, carcinoma, and metastasis [60]. The molecular 
mechanisms involved in these changes include activation 
of specific oncogenes and inactivation of tumor suppres-
sor genes [61, 62]. Cancer is a multifactorial disease due 
to genetic, epigenetic, and environmental factors [63]. 
CRC can be asymptomatic for many years. Malignancies 
on the right-side of colon, including the cecum, ascend-
ing, and descending colon are associated with fatigue, 
weakness and iron deficiency anemia; however, left 
colon neoplasms are associated with concealed bleeding, 
alterations in bowel movement, and lower left quadrant 
cramp. Diagnosis is often made by the detection of fecal 
occult blood testing followed by endoscopy; this is then 












Records deleted due to duplication  
(n=106)
Records screened  
(n = 391) Records excluded  
(n =189) 
















Additional records identified through other sources  
(n = 222)
Records identified through 
database searching  
(n = 275) 
Studies included in 
qualitative synthesis  
(n = 39)
Full-text articles excluded, 
with reasons  
(n = 163) 
Full-text articles assessed 
for eligibility  
(n = 202) 
Fig. 1 PRISMA flowchart of study selection
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involved in the development of some cancers, including 
CRC, is the role of infections on tumor suppressor genes 
in the initiation, progression, and metastasis of cancer 
[65].
The microbiota and colorectal cancer
Gut dysbiosis can promote CRC through various pro-
cesses that include: the induction of a chronic inflamma-
tory disease or immune response, biosynthesis of toxic 
metabolites and genotoxin and effect of host metabolism 
[66, 67]. Alternatively, Microbiota can prevent cancer by 
producing metabolites and enzymes. Although, some 
bacterial metabolites secreted from Enterococcus faecalis, 
enterotoxin Bacteroides fragilis or FadA in F. nucleatum 
are capable of damaging DNA, they can induce prolifera-
tion of colon cells in studies on gut microbiota in cancer 
patients [68]. Gut bacterial composition can be affected 
by environmental factors and tumour genomics [69]. 
Most cases of CRC are treatable if a diagnosis is made 
early enough. The survival rate in patients in whom an 
early detection is made is approximately 5 times greater 
than for patients diagnosed with advanced malignancies 
[70]. Consequently, it is necessary to evaluate valuable 
early diagnosis markers for CRC cases [70]. In the follow-
ing, we will discuss the role of F. nucleatum as a parame-
ter in the development and diagnosis of colorectal cancer.
Tumorigenic potential of Fusobacterium nucleatum
Sequences of Fusobacterium species were found to be 
enriched in colorectal carcinomas [71]. The results were 
confirmed with the use of quantitative PCR and sequence 
analysis of 16S rDNA performed on 95 normal-tumor 
pairs of DNA. In addition, Fusobacteria were observed 
in colorectal tumors by FISH. According to the obtained 
results, there are some changes in the microbiota in CRC 
[71]. F. nucleatum and some common bacteria were 
found in the primary tumors but also in distant metas-
tases [72]. Preliminary evidence indicates that this bac-
terium is initially found in cancer cells of metastasis type 
instead of the stroma. The tumor growth in mice with 
xenografts from of CRC containing F. nucleatum was 
reduced following treatment with antibiotics, consist-
ent with the causal role played by bacteria in the devel-
opment of tumors [20]. Preclinical rodent studies have 
recently shown that antibiotic therapy or the absence of 
the gut microbiota reduces the incidence of tumors in 
several murine colitis-associated CRC models [18]. The 
frequency of Fusobacterium in human tumors by the 
RNA-seq method was similar to the one obtained from 
mice tumors using flow cytometry [18]. In most cases, 
Fusobacteria are not part of the natural bacteria of the 
large intestinal flora. Studies show that cancerous tissues 
contain significantly more Fusobacteria [73]. Previous 
research has indicated that infection with this bacte-
rium increases the incidence of ulcerative colitis in which 
inflammation of the intestinal lining destroys the intesti-
nal cells and consequently is a risk factor for colorectal 
cancer [27].
The impact of diet on the microbiota and colorectal cancer
At birth, four main bacterial species are present in the 
gut: Firmicutes, Bacteriodetes, Proteobacteria and Actino-
bacteria [74]. They vary greatly among healthy individu-
als depending on environmental, genetic, host immune 
system, diet, and exposure to infection or antibiotics 
[20, 74]. Despite the considerable variation among indi-
viduals, it has been found that there are similar microbial 
populations in colorectum, including anaerobic bacteria 
such as Bacteroides, Eubacterium, Bifidobacterium, Fuso-
bacterium, Peptostreptococcus, Atopobium and optional 
anaerobes, including Lactobacilli, Enterococci and Enter-
obacteria. However, diet, age, gender, and ethnicity affect 
individual microbes, making its dynamic nature difficult 
investigate [8, 75]. From the 1990s onward, studies have 
shown an association between CRC and certain bacterial 
species [76]. Shen et  al., evaluated 21 adenomas and 23 
non-adenomas. In cancerous tissues, Proteobacteria is 
increased, and Bacteroidetes decreased [77]. It is possible 
that some probiotics facilitate immunomodulatory and 
anticancer activities in different contexts [10]. For exam-
ple, lactobacillus in the lactic acid bacteria group is the 
main probiotic organisms. Various reports have indicated 
that isolates of Lactobacillus spp. [10] like Lactobacillus 
acidophilus in different forms may increase the anticancer 
effects by different mechanisms such as downregulation 
of ErbB-2, activation of natural killer cells, dendritic cell 
maturation, and release of probiotic-derived ferrichrome 
(iron-scavenging peptide) [78, 79]. The microbiome has 
been called “The forgotten organ” [80, 81]. Microbiota 
can play a key role in the development of CRC by alter-
ing the bacterial composition of the intestine (dysbiosis), 
high production of some bacterial enzymes, changes in 
the distribution of bacterial communities and altera-
tion in bacterial metabolic activity [82, 83]. On the other 
hand, some of the components of the microbiota control 
the differentiation of intestinal epithelial cells and their 
proliferation, growth and development of the epithelial 
barrier, make strong apical bonds, protect against strains 
of pathogens, fermentation of carbohydrates indigestible 
for the production of short chain fatty acids (SCFA), bile 
acid metabolism and destruction of carcinogens in the 
diet in protection against cancer [84–87]. Many factors 
can alter the microenvironments of the digestive tract 
and consequently the bacterial flora, such as consump-
tion of antibiotics, mental and physical stressors, radia-
tion, and diet [88]. The microbiota play a significant role 
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in the regulation of inflammation, immune response or 
hematopoiesis among others [89]. Modification of the 
microbiota may lead to some pathologies such as depres-
sion and cancer [90, 91]. Prevention of carcinogenesis by 
modulating tumor or host cell microenvironment may 
be possible. Moreover, the microbiota has been found 
to influence chemotherapy, radiotherapy and immu-
notherapy efficacy and toxicity [80]. L.  casei probiotic-
derived ferrichrome has its anti-tumor effect through 
the pathway contributing to JNK-mediated apoptosis 
[92]. They are also associated with decreased polariza-
tion of pro-inflammatory TH17 cells and consequently a 
reduction in anti-inflammatory Treg cells differentiation 
(regulatory T cells) and/or gut Tr1 cells (T regulatory 
type 1 cells) in addition to anti-inflammatory metabo-
lites production [10, 93]. There is a special association 
between the microbiome profiles and cancer growth 
and progression. Consequently, interventions altering 
microbiome composition are likely to affect oncogen-
esis (Fig. 1). The microbiome may remain unchanged for 
many years. However, factors such as response to antibi-
otic therapy, exposure to pathogens, fasting, changes in 
daily diet composition and other causes such as stress, 
cold and diurnal rhythm disruption can cause perma-
nent changes in it [10]. Moreover, according to reports, 
microbiomes affect various traits ranging from metabo-
lism to mood [10]. The microenvironment of CRC is a 
complex community of genomically changed tumor cells, 
non-neoplastic cells, and a varied group of microorgan-
isms [71]. Many genetic and epigenetic factors affect the 
reported recurrence of the disease; in many studies, the 
gut microbiome has not been identified as an important 
factor in the disease occurrence. With the progress of 
advanced bowel sampling techniques and analysis of both 
Fig. 2  The main mechanism of F. nucleatum pathogenesis in CRC is illustrated. The adhesion and invasion of  FadA from F. nucleatum to 
epithelialand endothelial cells of human in pathway 1 can be observed while levels of  inflammatory cytokine (IL-6, IL-8,IL-10, IL-18, TNF‑α, and NF- κB) 
grow in a proinflammatory microenvironment which in turn leads to colorectal tumor progression; FadA interaction with E-cadherin in pathway 2 
in epithelial cells leads to  activating of  β-catenin signaling, increasing NF-κB inflammatory gene expression and enhancing tumor cell proliferation. 
F.nucleatum‑infected cells, on the other hand, enhance miRNA expression by Toll-like receptor activation and therefore miRNA release development. 
F.nucleatum in pathways 3 and 4 reduces the activity of human T cells in a micro‑suppressor of the tumor immune system. The interaction between 
Fap2 from F.nucleatum and the human inhibitor receptor TIGIT in pathway 5 leads to the death of lymphocyte cells of human, resulting in a 
microenvironment of immunosuppression that increases the progression of CRC 
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nucleic acid (RNA sequences) and protein (Proteome) 
products, it has been identified that the gut microbial 
community is a key component in not only in tumorigen-
esis but also the non-recurrence of disease after surgery 
[74, 94]. Most studies on the role of the microbiome on 
CRC recurrence have been investigated in clinical studies 
where local recurrence has occurred [74]. F. nucleatum 
can cause cancer by activating cellular signals through 
various mechanisms. These mechanisms are important 
for causing cancer in terms of cell surface receptors and 
their effects on the immune system (Fig. 2).
Doll and Peto have previously argued that 30% of the 
risk of cancer might be attributed to diet. Since then, 
much available evidence has pointed out that several 
nutrients can change cancer growth and progression 
[95]. Long-term dietary habits can shape the gut micro-
biota [87]. The International Agency for Research on 
Cancer (IARC), as part of the World Health Organization 
(WHO), has suggested that there is enough evidence to 
consider consumption of processed meat (Group 1) and 
red meat (Group 2A) in humans as having possible carci-
nogenic effects. IARC analyzed a group of half a million 
English men and women. In their analysis, they con-
cluded that processed meat and red alcohol were related 
to increased risk of colorectal cancer. They also demon-
strated an association between reduced risk of cancer 
and fiber in bread and breakfast cereals [96]. The inci-
dence and mortality of polygenic diseases like cancer vary 
depending on genetic susceptibility and environmental 
factors. Interaction of specific nutrients on genetic code 
exists in all nucleated cells [93]. For example, high con-
sumption of refined starches and sugar increases the pro-
duction of superoxide anion in leukocytes, mononuclear 
cells and free fatty acids (FFA) [97]. It also increases the 
levels and activity of the nuclear factor kappa-light-chain-
enhancer of activated B cells (NF-kB), a transcriptional 
regulator activating at least 125 genes, most of which are 
pro-inflammatory. Glucose intake also increases the two 
pro-inflammatory transcription factors; activated pro-
tein 1 (AP-1) and early growth response protein 1 (Egr-1) 
[98]. AP-1as a transcription factor induces regulation of 
the transcription of inflammatory cytokines, matrix met-
alloproteinase, as well as the transformation of apoptosis 
and cell proliferation [99]. Egr-1 induced endothelial gene 
expression [100], and modulation of transcription of tis-
sue factor and plasminogen activator inhibitor-1 (PAI-1) 
[98, 101]. Increased absorption of linoleic acid, saturated 
fat, trans fats, refined starches and sugars can increase 
the production of free radicals and NF-kB activation 
leading to rapid expression of pro-inflammatory genes 
[98]. Nutrients, antioxidants, micronutrients, minerals, 
vitamins, coenzyme Q10 and ω3 fatty acids may inhibit 
NF-kB superoxide production, AP-1, and Egr-1 [98]. The 
evidence indicates that dietary fiber, especially starch that 
is resistant to digestion, enhances intestinal health. One 
of the issues causing the starch to be the focus of empiri-
cal research is its potential protection against CRC devel-
opment [102]. Other studies have indicated that butyrate 
(main short-chain fatty acids) from resistant starch fer-
mentation through the bacteria in the gut causes physi-
ological changes in humans [103] and plays a significant 
role over the lifestyle in protecting the body against 
deteriorating metabolic control and inflammatory status 
associated with western lifestyles [104]. Although there is 
evidence of the cellular effects of butyrate, much research 
has been conducted to determine which mechanisms of 
butyrate can be used for antitumor applications [105]. 
Statistical and bioinformatics analysis was then per-
formed to determine which potentially important genes 
and proteins are involved in inducing apoptosis of colon 
cancer cells. Furthermore, 1347 proteins such as isoforms 
of protein and modifications were detected using prot-
eomics (2D-DIGE and mass spectrometry). Moreover, 
139 proteins were identified. These proteins were likely 
to play a role in the apoptotic response to butyrate [93]. 
These reactions, along with the microbial population in 
the gastrointestinal tract, particularly the large intes-
tine, cause the formation of microbiomes, including all 
microorganisms, their genes and metabolites. Extensive 
investigations to find out the genetic map of microor-
ganisms are in progress, since microbial genes and their 
interactions with body cells exist before, during, and after 
illnesses.
Factors affecting the intestinal microbial 
population
Most studies indicate that the composition of the intes-
tinal microbiota is formed before the age of three and 
then has a constant composition throughout life [106, 
107]. Some factors such as the use of antibiotics, spe-
cial diet, and chemotherapy can interfere with the struc-
ture of the gut microbiota [108]. Since the microbiota 
plays an important role in the normal functioning of the 
body, today it is considered an organ created at birth and 
evolves with us. The role of the microbiota in the devel-
opment of some gastrointestinal diseases has been dem-
onstrated [109]. These diseases can range from causing 
inflammation to colon cancer [110]. The gut microbiota 
may also sometimes be involved in the development of 
extra-intestinal immunological diseases [110, 111]. Pro-
biotics such as bifidobacteria, lactobacillus, bacteroids 
are mainly found in the colorectal and are beneficial for 
human health. They control the population of patho-
genic bacteria by producing short-chain fatty acids such 
as acetic, butyric and propionic acid. Prebiotics are also 
a substrate choice for the growth of beneficial bacteria 
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like bifidobacteria. Prebiotic foods include sugars such as 
inulin and oligofructose (FOS). During breastfeeding, the 
major bacterium in neonatal feces is bifidobacteria, but 
during weaning, the level of bifidobacteria is decreased 
and other bacteria such as coliform, Clostridium and 
Streptococcus are increased [112]. As more molecular 
techniques and bioinformatics analyses were developed, 
a better understanding of a healthy microbiome or dis-
ruption of the microbial community, including loss of 
beneficial bacteria or loss of diversity among them, was 
achieved [74]. The disorder produces a specific condition 
called dysbiosis, which means the loss of the health-pro-
moting microbiome known as disease-producing patho-
gens. Numerous studies have shown that Fusobacterium, 
Alistipes, Porphyromonadaceae, Coriobacteridae, Staph-
ylococca-ceae, Akkermansia, Lactobacillus, Faecalibacte-
rium, Roseburia and Treponema are present in patients 
with CRC [58, 113–118]. The present findings emphasize 
the importance of cell-bacterial interactions in a net-
work. Various mechanisms such as aberrant activation 
of immune cells, induction of DNA damage through pro-
duction of oxygen and nitrogen species, and increased 
levels of immunocyte-derived bioactive molecules facili-
tate tumor progression [16]. Using an antibody neutrali-
zation assay, an important role for epithelial expression of 
TLR2 was identified in this process [119]. These findings 
are consistent with the recent role of TLRin the develop-
ment of colorectal cancer.
Fusobacterium as a biomarker in CRC 
Fusobacterium is a genus of anaerobic, Gram-negative, 
non-spore forming bacteria, similar to Bacteroides. F. 
nucleatum and F. necrophorum are usually members of 
the Fusobacterium species. They usually reside in the 
oral cavity and sometimes cause periodontal and gum 
infections [9]. Fusobacterium is considered a risk factor 
involved in CRC start and improvement. Immune modu-
lation is considered to be the most important mechanism 
of Fusobacterium playing a role in CRC carcinogenesis 
(Fig.  1). It includes increased cells of myeloid-derived 
suppressor and natural killer cell inhibitors, FadA and 
Fap2 virulence factors, microRNAs and bacterial metab-
olism [120, 121].
Carcinogenesis mechanisms of F. nucleatum
Tumorigenesis mechanism of Fusobacteria includes 
receptors of pattern recognition and downstream inflam-
mation, but these bacteria with the recruitment of 
myeloid cells lead to infiltration of adenomas and car-
cinomas, thereby resulting in NF-κB-dependent TLR4 
signaling [122]. Recently, it has also been demonstrated 
that F. nucleatum leads to increased expression of inflam-
matory mediators (IL1B, IL6 and IL8) [40, 119]. This is 
possibly due to miRNA-mediated activation of TLR2/
TLR4 [75, 119]. In the immune response to bacterial 
infection, TLRs are highly important. Among them, 
TLR4 is considered a representative receptor for LPS. 
When TLR4 is activated by LPS, a series of intracellular 
events are triggered. This leads to nuclear translocation 
of NF-κB, thereby increasing the expression of IL-8 gene 
[123]. However, F. nucleatum doesnot encode any known 
toxins, while only few common virulence factors are 
encoded by it. Adhesion protein FadA is a known viru-
lence factor in F. nucleatum contributing to easier attach-
ment and invasion of bacteria [124, 125]. FadA binds with 
an E-cadherin receptor and increases carcinogenesis. 
It causes activation of β-catenin and stimulates expres-
sion of transcriptional factors, Wnt genes, inflammatory 
genes, and related oncogenes (Fig. 1) [126]. In this adhe-
sion process, MORN2 may also be involved. However, the 
exact function of MORN2 is unknown [126]. When FadA 
adhesin from F. nucleatum binds with CDH1, it causes 
an increase in the proliferation of Fusobacterium/WNT 
[126]. FadA and MORN2 proteins of F. nucleatum play 
a key role in cell invasion [127]. FadA is a small ligand 
(125 AA) present on the surface of Fusobacterium, which 
has been shown to bind to E-Cadherin and activates 
β-catenin signaling in human cancer xenografts of mice 
models [112]. Thus, FadA binding is directly involved in 
host cell binding and invasion of Fusobacterium. MORN2 
proteins further contain a signal sequence allowing the 
transfer of small peptides into the periplasmic space and 
from the outer membrane to the extracellular environ-
ment [112]. Among the empirically identified proteins 
associated with disease severity is Fap2 lectin, a galac-
tose adhesion protein, which binds with the NK Cell 
Receptor TIGIT and inhibits the destruction of tumor 
cells by inhibiting NK cells. Fusobacterium binds with 
the Gal-GalNAc receptor on the surface of colon cancer 
cells, thereby producing proinflammatory cytokines and 
proliferating cancer cells [128]. Metagenomic analyses 
have indicated increased Fusobacterium species in CRC 
compared to adjacent normal tissue by total genome 
sequencing, transcriptome sequencing or by 16S rRNA 
gene sequencing used as a tool to identify bacteria 
[120, 121, 129]. There has been a correlation between F. 
nucleatum in CRC, chemo-resistance and poor progno-
sis. According to what mentioned before, binding of the 
Fap2 protein of F. nucleatum with the inhibitory recep-
tor TIGIT of human protects tumors from immune cell 
attack expressed in natural killer (NK) cells. F. nucleatum 
would also inhibit T and NK cell activities [18]. The fol-
lowing section describes the other five extensive families 
of pattern recognition receptors (PRRs). They include 
CLRs (C-type lectin receptors), LRR (nucleotide-bind-
ing domain leucine-rich repeat) containing (NOD-like) 
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receptors (NLRs), RLRs (RIG-I-like receptors), ALRs 
(AIM2-like receptors) and cytoplasmic DNA sensors 
[122]. Recent research activities emphasize the impor-
tance of pathogen–host signaling, by PRRs in the whole 
range of inflammatory responses, including cancer devel-
opment and inhibition [130]. PRRs signaling impacts all 
stages of intestinal cancer, from the early stages of can-
cer to the metastatic stage and appearance of different 
cells in the tumor microenvironment, and from neo-
plastic cells to tumor and stromal cells [122, 130]. Small 
secretory peptides bind to myeloid-derived suppressor 
cells (MDSCs), thereby inhibiting CD4+ T cell. Inhibi-
tion of immune cells would be desirable for tumor cells, 
since it will spread the tumor to other parts of the body 
[112]. Investigation of 16 s rRNA sequencing of increased 
F. nucleatum levels in mucosal or fecal samples of CRC 
patients has shown that F. nucleatum levels in CRC tis-
sue is associated with the tumor site of right-sided proxi-
mal colorectum and CpG island methylator phenotype 
(CIMP) status, microsatellite instability (MSI) and muta-
tions in BRAF, KRAS, CHD7, CHD8 and TP53 genes 
[131]. Increased inflammatory cytokines such as NF-KB, 
TNF-α, IL10, IL8, IL6, and increased levels of E. cadherin 
on epithelial cells activates B-catenin signaling, increases 
NF-κB, C-myc expression and proliferates tumor cells 
[70]. Cells infected with F. nucleatum, due to activation 
of Toll-like receptors (TLR), cause more mRNA expres-
sion and release. F. nucleatum induces lymphocyte cell 
death and tumor progression by blocking G1 phase cell 
myeloid derivative suppressor cells (MDSCs) and TIGIT 
receptor inhibition [52, 132]. F. nucleatum also affects the 
IL-6-STAT3 axis signaling and induces tumorigenesis by 
directly interacting with epithelial cells through activat-
ing TLRs. The key molecules stimulating tumor growth 
and invasion induced by these bacteria include IL-6, cyc-
lin D1, TNFα, MMP9 and heparanase [127].
F. nucleatum, immunomodulatory of the tumor 
microenvironment
Cancer in its simplest form of uncontrolled cell growth 
in association with F. nucleatum is likely to affect the 
proliferation of cancer cells in the colorectal. Accord-
ing to epidemiological associations, F. nucleatum can 
improve instability and mutation of genes [56]. In the 
stool of mice with colon cancer, there was a correlation 
between immunotherapy by antibodies for IL.10 recep-
tor (antiIL10R) and CpG oligodeoxynucleotides with 
the increased Alistipes shahii. In this model, A. shahii 
caused an increase in the production of the tumor necro-
sis factor (TNF) by intrauterine myeloid cells, while 
TNF neutralization abolished the therapeutic effect 
[10]. It has been reported that enterotoxigenic B. fragi-
lis stimulate pro-inflammatory Th17 cells that accelerate 
carcinogenesis in mice prone to the tumor [10, 79]. Com-
pared to different bacterial strains, F. nucleatum can cor-
rectly identify patients with CRC. Recent studies have 
shown that F. nucleatum DNA in the early stages of the 
disease has the diagnostic potential as a non-invasive pri-
mary biomarker for CRC from fecal samples [52]. Fuso-
bacterium is associated with the signature of human CRC 
gene expression. A correlation of immune cell marker 
genes, including tumor-associated macrophages (TAMs) 
(CD209, CD206/MRC1, IL6, IL8, and CXCL10), MDSCs 
(CD33 and IL6), dendritic cells (DCs) (CD11c/ITGAX, 
CD209, TNF, and CD80) and Fusobacterium has been 
found in humans [18]. Some T cell subsets are associated 
with CRC prognosis. For example, Th1 subsets detected 
by interferon-gamma secretion (IFNγ) with better prog-
nosis and Th17 identified due to IL-17 production are 
accompanied by a worse prognosis. Several studies have 
shown that Fusobacteria, in particular Fusobacterium, 
is also prevalent in CRC tissues despite being predomi-
nant in the oral microbiome. Using tissues from CRC 
patients that were positive for the 16S ribosomal RNA 
gene Fuso sequence and Th1 and Th17 cell populations 
in CRC patients by flow cytometer, there was a positive 
relation with both IL-17+ and IFNγ+ cytokines. These 
findings suggest that immune responses in CRC patients 
(Th1 and Th17) correlate with the frequency of Fusobac-
terium, especially the nucleatum [56]. Fusobacterium-
related genes, including PTGS2 (COX-2), IL1b, IL6, IL8 
and TNF, are expressed not only in colon cancer but also 
in cultures of human and mouse cell lines in vitro known 
as the central link between inflammation and cancer 
[18]. In general, the expression of human Fusobacterium-
dependent proinflammatory genes is higher in colorectal 
tumors than in small bowel tumors. This may be due to 
the anatomical location related to the fact that the listed 
genes are derived from human CRC [18]. Mouse stud-
ies have indicated that the gut microbiome may regulate 
local immune responses and affect chemotherapy and 
immunotherapy [74]. In patients with colorectal cancer, 
autophagy pathways are rich and active and high levels 
of F. nucleatum cause resistance to chemotherapy [45]. 
F. nucleatum binds with the host epithelial E-cadherin 
and stimulates colorectal carcinogenesis through Fuso-
bacterial adhesion FadA [74]. It has also been found 
that F. nucleatum targets micro-RNA and autophagy 
Signaling via upregulation of CARD3 expression caus-
ing resistance to chemotherapy [26, 45]. The direct asso-
ciation of Fusobacterium with recurrent CRC has even 
been postulated as a way to predict disease outcomes 
or change chemotherapy regimens such as inclusion 
of capecitabine and oxaliplatin for patients with a high 
burden of F. nucleatum [45]. These observations suggest 
further consideration of antimicrobial interventions as 
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a potential treatment for patients with CRC related to 
Fusobacterium [131]. One concern is the negative effect 
of broad-spectrum antibiotics on the intestinal microbi-
ome [20]. Metronidazole is ideal, since it targets various 
anaerobic bacteria, including Fusobacterium anaerobic 
bacteria. Fusobacteria are highly sensitive to metroni-
dazole. Finally, oral administration of metronidazole to 
mice that were Fusobacterium- positive resulted in a sig-
nificant decrease in tumor growth pathways. Treatment 
with metronidazole resulted in a significant reduction in 
the Fusobacterium burden [20]. However, antibiotics are 
somewhat similar to cytotoxic chemotherapy, and their 
treatment is relatively non-targeted. Enterotoxigenic Bac-
teroides fragilis (ETBF) is a toxin-producing bacterium 
that can activate  TH17-mediated colitis, with simultane-
ous colon-specific STAT3 activation and tumor stimula-
tion in susceptible ApcMin (Multiple Intestinal Neoplasia) 
mice, which is reversed by IL-17 antibody blockade [133]. 
This issue is also considered a limitation for the treat-
ment method. Other bacteria involved in CRC may also 
respond to tumor progression even beyond antibiotics. 
Nevertheless, as shown with metronidazole treatment, 
even in the late stages of the disease, it may response to 
clear Fusobacterial colonization of carcinomas in experi-
mental mice models [134]. A recent study has shown that 
colorectal tumors with a high Fusobacterium burden 
are likely to recur, implying that Fusobacterium-positive 
tumors may benefit from anti-Fusobacterial treatment 
[20].
Fusobacterium‑associated microRNAs
MicroRNAs (MiRNAs) are non-coding molecules of 
RNA with approximately a length of 19–25 nucleo-
tides. At the post-transcriptional level, they regulate 
target genes expression negatively. It has been shown 
that oncogenic miRNAs (clusters of miR-17-92a and 
miR-25-106b [13]) play an active role in CRC pro-
gression [135]. Moreover, it has been shown that dif-
ferent miRNAs such asmiR-21, miR-224, miR-200c 
miR-96, miR-135, miR-31, and miR-155 are related to 
pathogenesis of CRC [136, 137]. The microarray analy-
sis results showed the active role of 49 miRNAs in F. 
nucleatum induced CRC, while in a Multi-Class-Dif 
analysis, there was a significant expression of 96 miR-
NAs in early and advanced stages of CRC with positive 
infection of F. nucleatum [13]. Among different expres-
sions of miRNAs, miR-4474 and miR-4717 expressions 
were upregulated in CRC with positive infection of 
F. nucleatum [13]. Other genes, including CREBBP 
(CREB-binding protein), STAT1, CAMK2B, PRKACB, 
JUN, TP53 and EWSR1, which were involved in cancer 
signaling pathways were dysregulated [13]. MiR-4802 
and miR-18a* are abnormally reduced in expression 
by F. nucleatum that has been also known to induce 
chemoresistance to oxaliplatin and 5-FU by reduc-
tion of apoptosis through the activation of autophagy 
and TLR4/MYD88 signaling [138]. Enrichment of 
Fusobacterium species is observed in the microbiota 
in carcinomas near healthy colonic tissue. They are 
observed in stool samples obtained from CRC patients 
at a higher degree compared to healthy controls. In the 
early stages of tumorigenesis, F. nucleatum that is usu-
ally present in the oropharynx [139], is in not only car-
cinomas but also colorectal adenomas [21].
Perspective and conclusion
The gut microbiota is the largest reservoir of human 
microbiota. They consist of species of microorganisms 
living in the gastrointestinal tract in coexistence with 
the host, reaching a population of tens of  1014 [140]. 
They include at least 1000 different species of known 
bacteria containing more than 3 million genes (150 
times more than human genes) [140–142]. Although 
more than a thousand different species of bacteria are 
found in the human gut, only 150 to 170 of them are 
common in different individuals [141]. Microbiota of 
each person is distinctive. Therefore, the identification 
and determination of normal microbiota in different 
societies and ages are an important factor and a prereq-
uisite for further identification of the influencing fac-
tors. A healthy and balanced gut microbiota is the key 
to ensuring proper digestive function [143]. They also 
play a crucial role in the immune system and play a vital 
role in a mucosal barrier [144]. Other important roles 
of the gut microbiota are to help digest certain foods 
that the stomach and small intestine cannot digest, 
produce some vitamins (B and K), help protect against 
other microorganisms and maintain intestinal integ-
rity. In some cases, a change in the composition of the 
microbiota can interfere with its balance, called dysbio-
sis. Intestinal microbiota dysbiosis can cause intestinal 
diseases such as inflammatory gut disease, irritable gut 
syndrome, CRC and extra-intestinal diseases such as 
diabetes, obesity, cardiovascular disease, non-alcoholic 
fatty liver disease, liver cells and decreased mental 
health [145–148]. Researchers at the Wyss Institute at 
Harvard, engineered the E. coli strain as a probiotic-gut 
bacterium producing a network of nanofibers that were 
directly attached to the mucosa [149]. This strain fills 
the inflamed areas like a patch and protects these areas 
from environmental factors and gut microbes. This 
probiotic-based treatment improved rats with chemi-
cal agents and increased mucosal healing. Although 
many studies have focused on the local delivery of anti-
inflammatory drugs to fistulae, ulcers, and intestinal 
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inflammation, fewer studies have been conducted on 
mucosal healing that plays an important role in sup-
pressing these diseases. Matrix contributes to fibrosis 
to repair intestinal epithelial [149]. This matrix con-
tains Curli nanofibers, known as an intestinal barrier 
enhancer and an epithelial enhancer. The researchers 
maintain that this method can produce engineered bac-
teria that will settle in the gut and secrete the desired 
biomaterials [149]. The consumption of yogurt, kefir 
(a kind of yogurt drink), cheese, fruits and vegetables, 
seafood, avoiding foods made with preservatives and 
taking probiotic supplements can be effective in main-
taining the normal gut microbiota balance [150]. It is 
still unknown whether F. nucleatum colonization is the 
outcome or a cause of carcinogenesis or inflammation 
in colorectal tissue. The results produced some intrigu-
ing results representing Fusobacterium sp. as a poten-
tial biomarker for colorectal carcinogenesis. Above all, 
these results provide a mechanistic insight indicative 
of the mediation of Fusobacterium sp. actions through 
FadA binding to host epithelial cells’ receptors in order 
to change the function of barrier, to increase inflam-
mation through modulation of the microenvironment 
of tumor, and to activate pro-oncogenic signals for 
CRC promotion. These findings can affect the preven-
tion, diagnosis and treatment of CRC. However, further 
studies are required for evaluation of the FadA diagnos-
tic potentiality. More certain answers on the temporal 
order between F. nucleatum and CRC can be found in 
prospective studies. Even though F. nucleatum coloni-
zation may result from colorectal cancer, nevertheless 
it may play a key role in tumor malignancy increasing, 
metastasis promoting and antitumor immunity evasion. 
Some interesting questions have been raised on cancer 
causes based on the role of F. nucleatum in tumorigen-
esis. It is possible to reduce the development of cancer 
through manipulation of bacterial microbiota by fecal 
microbial implants, probiotics and using antibiotic 
treatments or vaccination. Although fecal F. nuclea-
tum may be a considered as a proper measurable bio-
logical marker for detection of CRC; further research 
is required to make it clear how it changes in different 
stages of colon cancer. A combination of microbiome 
modulation and its products with simpler immuno-
therapy approaches directly targeting malignant cells 
could be used in the future for antineoplastic therapy. 
The importance of this method is in the new antican-
cer method or enhanced therapeutic drugs against 
cancer. This method will have positive clinical results 
for patients with cancer. Oncomicrobiotics (cocktail 
of bacteria or bacterial products) is a new supportive 
treatment for cancer improving immune responses by 
enhanced gut function. Therefore, much more research 
is needed to be conducted on cross talk between host–
bacteria and their virulence proteins that play a role in 
colorectal carcinogenesis.
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